 NEW YORK, June 29, 2021 PRNewswire -- DarioHealth Corp. Nasdaq: DRIO, a leader in the global digital therapeutics DTx market, presented new clinical research today at the American Diabetes Association ADA 81st Scientific Sessions, the premier diabetes conference for cutting-edge research and advances in diabetes care. Darios latest research examines the impacts of the companys artificial intelligence AI-driven personalization engine on user engagement and clinical outcomes for close to 10,000 members. 